Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
Anita Mathias(Gilead Sciences (United States)), Brian P. Kearney(Gilead Sciences (United States)), Steve West(Gilead Sciences (United States)), James Hoi Po Hui(Gilead Sciences (United States)), Aakanksha Jain(Boston Children's Hospital), Bernard P. Murray(Gilead Sciences (United States)), David R. Warren(Gilead Sciences (United States)), Lilian Wei(Gilead Sciences (United States)), Polina German(Gilead Sciences (United States))
Cited by 208
Related Papers
Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia
|Science Advances|2024|194
Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm
|The Journal of Immunology|2017|171
T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells
|Nature Communications|2018|139
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
|The Journal of Infectious Diseases|2010|114